Skip to main content

Table 2 Indications to radical cystectomy after EMDA-MMC treatment

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Recurrent HGNMIBC, n° of patients (%)

6 (23.1%)

 TaG3

1 (3.8%)

 T1G3

2 (7.7%)

 Cis

1 (3.8%)

 Ta/T1G3 + Cis

2 (7.7%)

Evidence of MIBC, n° of patients (%)

4 (15.4%)

 T2

3 (11.5%)

 T4

1 (3.8%)